Similar articles

• Single center randomized trial using ATG v OKT3 treatment in steroid resistant rejection crises after kidney transplantation.

  Blümke M, Kirste G, Wanner U, Wilms H. Blümke M, et al. Transplant Proc. 1989 Feb;21(1 Pt 2):1747. Transplant Proc. 1989. PMID: 2652571 Clinical Trial. No abstract available.
• Histologic response to OKT3 therapy for hepatic allograft rejection.

  Rohrer RJ, Jenkins RL, Khettry U, Benotti PN, Dodson TF, Karlson CG, Georgi BA, Monaco AP. Rohrer RJ, et al. Transplant Proc. 1987 Feb;19(1 Pt 3):2459-61. Transplant Proc. 1987. PMID: 3079086 Clinical Trial. No abstract available.
• OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children.

  Woodle ES, Thistlethwaite JR Jr, Emond JC, Whitington PF, Black DD, Aran PP, Baker AL, Stuart FP, Broelsch CE. Woodle ES, et al. Transplant Proc. 1990 Aug;22(4):1765-6. Transplant Proc. 1990. PMID: 2117803 No abstract available.
• Clinical development of Orthoclone OKT3.

  Cosimi AB. Cosimi AB. Transplant Proc. 1987 Apr;19(2 Suppl 1):7-16. Transplant Proc. 1987. PMID: 3105142 Review. No abstract available.
• Monoclonal antibody treatment of human allograft recipients.

  Delmonico FL, Cosimi AB. Delmonico FL, et al. Surg Gynecol Obstet. 1988 Jan;166(1):89-98. Surg Gynecol Obstet. 1988. PMID: 3276014 Review.